BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 36921274)

  • 1. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
    Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 71(53):1637-1646. PubMed ID: 36921274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
    Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1616-1624. PubMed ID: 36580430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
    Surie D; DeCuir J; Zhu Y; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Ali H; Taghizadeh L; Gong MN; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Columbus C; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Hart KW; Swan SA; Lewis NM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1625-1630. PubMed ID: 36580424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
    Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
    Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
    Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
    Sane Schepisi M
    Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
    Link-Gelles R; Weber ZA; Reese SE; Payne AB; Gaglani M; Adams K; Kharbanda AB; Natarajan K; DeSilva MB; Dascomb K; Irving SA; Klein NP; Grannis SJ; Ong TC; Embi PJ; Dunne MM; Dickerson M; McEvoy C; Arndorfer J; Naleway AL; Goddard K; Dixon BE; Griggs EP; Hansen J; Valvi N; Najdowski M; Timbol J; Rogerson C; Fireman B; Fadel WF; Patel P; Ray CS; Wiegand R; Ball S; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(21):579-588. PubMed ID: 37227984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023.
    Link-Gelles R; Ciesla AA; Rowley EAK; Klein NP; Naleway AL; Payne AB; Kharbanda A; Natarajan K; DeSilva MB; Dascomb K; Irving SA; Zerbo O; Reese SE; Wiegand RE; Najdowski M; Ong TC; Rao S; Stockwell MS; Stephens A; Goddard K; Martinez YC; Weber ZA; Fireman B; Hansen J; Timbol J; Grannis SJ; Barron MA; Embi PJ; Ball SW; Gaglani M; Grisel N; Arndorfer J; Tenforde MW; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(33):886-892. PubMed ID: 37590187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
    Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.